Discover key insights from SANUWAVE Health's Q2 2025 earnings call, highlighting record revenue growth, strong UltraMIST sales, and strategic growth plans.

Comparable RevPAR growth in Q2 2025 was 0.1%. Total RevPAR growth was 1.1% due to a 4.2% increase in out-of-room revenues per occupied room, which reached a quarterly high of $160 per occupied room.

Q2 2025 Management View Kevin David Strain, President and CEO, emphasized "the strength and the resilience of our balanced and diversified business model," highlighting underlying EPS of $1.79, a 4% ...

Despite SBI's minimal direct exposure to sectors affected by US tariffs, chairman C.S. Setty is concerned that the broader ...

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

Net Profit rises 10.5% at Rs 57.3 crore versus Rs 51.8 crore.Revenue rises 26.3% to Rs 562 crore versus Rs 445 crore.Margin at 17.6% versus 19.4%.Ebitda rises 14.3% to Rs 98.7 crore versus Rs 86.4 ...

The impact of tariffs and foreign exchange rates squeezes Nikon's profits, despite strong sales of the Z5 II and Z50 II ...

Digital payments company Infibeam reported a 72% surge in revenue to Rs 1,280 crore for Q1 FY26, while its year-on-year ...

MobiKwik is tightening costs and chasing profitability, with hopes to turn EBITDA-positive by next couple of quarter, even as ...

R&D expense was $11.7 million for the three months ended June 30, 2025, compared to $7.6 million for the same period in 2024. The increase was primarily driven by higher research, development, ...

Even with a substantial 40%+ surge thus far this year, the stock continues to trade at a reasonable forward price-to-earnings ...

Revenue for Q1 FY2026 (GAAP) was $555.9 million, falling 16% short of analyst estimates. Adjusted diluted EPS (Non-GAAP) for Q1 FY2026 was $(0.32), beating non-GAAP EPS estimates. Television ...